{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:50:30Z","timestamp":1791924630538,"version":"4.3.4"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018525","name":"Key Research and Development Program of Sichuan Province","doi-asserted-by":"publisher","award":["20ZDYF1870"],"award-info":[{"award-number":["20ZDYF1870"]}],"id":[{"id":"10.13039\/501100018525","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014213","name":"National Institute of Science and Technology For Ocean and Maritime Studies","doi-asserted-by":"publisher","award":["2021-YF05-02246-SN"],"award-info":[{"award-number":["2021-YF05-02246-SN"]}],"id":[{"id":"10.13039\/501100014213","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.biopha.2022.113236","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T14:35:47Z","timestamp":1654785347000},"page":"113236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases"],"prefix":"10.1016","volume":"152","author":[{"given":"Fuxun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunping","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2022.113236_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the TH1\/TH2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113236_bib2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis--a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"15","key":"10.1016\/j.biopha.2022.113236_bib3","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/febs.14818","article-title":"The extracellular matrix as a multitasking player in disease","volume":"286","author":"Theocharis","year":"2019","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metab. Clin. Exp."},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib5","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113236_bib6","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","author":"Marso","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113236_bib7","article-title":"Rasmussen, soren, mann, johannes FE: liraglutide and renal outcomes in type 2 diabetes","author":"Orsted","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2022.113236_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"NEW Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2022.113236_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/jcbfm.2011.51","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia","volume":"31","author":"Teramoto","year":"2011","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2022.113236_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.freeradbiomed.2021.10.034","article-title":"Glucagon-like peptide-1 receptor activation maintains extracellular matrix integrity by inhibiting the activity of mitogen-activated protein kinases and activator protein-1","volume":"177","author":"Peng","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2022.113236_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2018.03.004","article-title":"The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis","volume":"131","author":"Li","year":"2018","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib12","doi-asserted-by":"crossref","first-page":"F458","DOI":"10.1152\/ajprenal.00128.2020","article-title":"Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt\/\u03b2-catenin signaling","volume":"319","author":"Huang","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1479164115605000","article-title":"Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis","volume":"13","author":"Gaspari","year":"2016","journal-title":"Diabetes Vasc. Dis. Res."},{"issue":"10019","key":"10.1016\/j.biopha.2022.113236_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.biopha.2022.113236_bib16","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/en.2012-1786","article-title":"Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats","volume":"154","author":"Roman\u00ed-P\u00e9rez","year":"2013","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.biopha.2022.113236_bib18","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1210\/en.2014-1685","article-title":"Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats","volume":"156","author":"Roman\u00ed-P\u00e9rez","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113236_bib19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fpubh.2020.00196","article-title":"Diabetes mellitus contributes to idiopathic pulmonary fibrosis: a review from clinical appearance to possible pathogenesis","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Public Health"},{"key":"10.1016\/j.biopha.2022.113236_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.peptides.2017.12.007","article-title":"Exendin-4 partly ameliorates - hyperglycemia-mediated tissue damage in lungs of streptozotocin-induced diabetic mice","volume":"99","author":"Oztay","year":"2018","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.21037\/atm-21-869","article-title":"Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a)","volume":"9","author":"Liu","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"8","key":"10.1016\/j.biopha.2022.113236_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41591-018-0087-6","article-title":"Metformin reverses established lung fibrosis in a bleomycin model","volume":"24","author":"Rangarajan","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib23","doi-asserted-by":"crossref","first-page":"15601","DOI":"10.1038\/s41598-019-51648-1","article-title":"Empagliflozin and dulaglutide are effective against obesity-induced airway hyperresponsiveness and fibrosis in a murine model","volume":"9","author":"Park","year":"2019","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.biopha.2022.113236_bib24","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1073\/pnas.84.16.5788","article-title":"Transforming growth factor type beta induces monocyte chemotaxis and growth factor production","volume":"84","author":"Wahl","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib25","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190103","article-title":"Transforming growth factor-\u03b2 in tissue fibrosis","volume":"217","author":"Frangogiannis","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bbrc.2005.10.209","article-title":"Smad3 mediates TGF-beta1-induced collagen gel contraction by human lung fibroblasts","volume":"339","author":"Kobayashi","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0002-9440(10)62351-6","article-title":"Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis","volume":"166","author":"Willis","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib28","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1038\/s41598-020-74912-1","article-title":"GLP-1 receptor agonist ameliorates experimental lung fibrosis","volume":"10","author":"Fandi\u00f1o","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2014.07.010","article-title":"Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-\u03baB in mice","volume":"22","author":"Si","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib30","doi-asserted-by":"crossref","first-page":"E568","DOI":"10.1152\/ajpendo.00292.2020","article-title":"Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein","volume":"319","author":"Zhou","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41374-018-0170-0","article-title":"Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function","volume":"99","author":"Xu","year":"2019","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1165\/rcmb.2009-0031OC","article-title":"Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis","volume":"43","author":"Hashimoto","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-017-0660-4","article-title":"Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition","volume":"18","author":"Suzuki","year":"2017","journal-title":"Respir. Res."},{"issue":"10","key":"10.1016\/j.biopha.2022.113236_bib34","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00125-010-1831-8","article-title":"A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells","volume":"53","author":"Hattori","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2022.113236_bib35","article-title":"Stimulation of the endogenous incretin glucose-dependent insulinotropic peptide by enteral dextrose improves glucose homeostasis and inflammation in murine endotoxemia","author":"Shah","year":"2017","journal-title":"Transl. Res."},{"issue":"7","key":"10.1016\/j.biopha.2022.113236_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/1535370218761628","article-title":"Featured article: TGF-\u03b21 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts","volume":"243","author":"Cho","year":"2018","journal-title":"Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1536\/ihj.51.348","article-title":"BAY 11-7082, a nuclear factor-\u03baB inhibitor, reduces inflammation and apoptosis in a rat cardiac ischemia-reperfusion injury model","volume":"51","author":"Kim","year":"2010","journal-title":"Int. Heart J."},{"key":"10.1016\/j.biopha.2022.113236_bib38","first-page":"8","article-title":"GLP-1 analog liraglutide improves vascular function in polymicrobial sepsis by reduction of oxidative stress and inflammation","author":"Helmst\u00e4dter","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2022.113236_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114956","article-title":"The paradox of dipeptidyl peptidase IV inhibition in enterocytic differentiation and epithelial-mesenchymal transition in rat cholestatic sepsis","volume":"394","author":"Zaky","year":"2020","journal-title":"Toxicol. Appl. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2022.113236_bib41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/1755-5922.12317","article-title":"Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor \u03b1-mediated activation","volume":"36","author":"Garczorz","year":"2018","journal-title":"Cardiovasc Ther."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/db06-1163","article-title":"Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism","volume":"56","author":"Westermann","year":"2007","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib43","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pharep.2017.10.003","article-title":"Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway","volume":"70","author":"Gallego-Colon","year":"2018","journal-title":"Pharm. Rep."},{"issue":"22","key":"10.1016\/j.biopha.2022.113236_bib44","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1111\/bph.13686","article-title":"Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction","volume":"174","author":"Esposito","year":"2017","journal-title":"Br. J. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib46","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ajpath.2015.12.017","article-title":"Myocardial galectin-3 expression is associated with remodeling of the pressure-overloaded heart and may delay the hypertrophic response without affecting survival, dysfunction, and cardiac fibrosis","volume":"186","author":"Frunza","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","article-title":"Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages","volume":"111","author":"Tate","year":"2016","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.biopha.2022.113236_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173318","article-title":"Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR\/p70S6K signaling and promoting autophagy","volume":"883","author":"Zheng","year":"2020","journal-title":"Eur. J. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bbadis.2014.06.030","article-title":"Interplay of oxidative, nitrosative\/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy","volume":"1852","author":"Varga","year":"2015","journal-title":"Biochim. Et. Biophys. Acta BBA Mol. Basis Dis."},{"issue":"9","key":"10.1016\/j.biopha.2022.113236_bib50","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00210-015-1124-3","article-title":"Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes\/macrophages","volume":"388","author":"Bu\u0142dak","year":"2015","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib51","doi-asserted-by":"crossref","first-page":"H295","DOI":"10.1152\/ajpheart.00990.2012","article-title":"Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes","volume":"305","author":"Monji","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"7","key":"10.1016\/j.biopha.2022.113236_bib52","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1210\/en.2013-1096","article-title":"Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male zucker obese rats","volume":"154","author":"Aroor","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113236_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111005","article-title":"Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1\/2\/NF-\u03baB signalling pathway","volume":"518","author":"Fan","year":"2020","journal-title":"Mol. Cell Endocrinol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.taap.2012.01.013","article-title":"Aspirin suppresses cardiac fibroblast proliferation and collagen formation through downregulation of angiotensin type 1 receptor transcription","volume":"259","author":"Wang","year":"2012","journal-title":"Toxicol. Appl. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10557-015-6592-7","article-title":"Preservation of glucagon-like peptide-1 level attenuates angiotensin ii-induced tissue fibrosis by altering AT1\/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart","volume":"29","author":"Zhang","year":"2015","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"10","key":"10.1016\/j.biopha.2022.113236_bib56","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/aps.2016.72","article-title":"Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro","volume":"37","author":"Wang","year":"2016","journal-title":"Acta Pharm. Sin."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1074248420942007","article-title":"Liraglutide attenuates myocardial fibrosis via inhibition of AT1R-mediated ROS production in hypertensive mice","volume":"26","author":"Chen","year":"2021","journal-title":"J. Cardiovasc. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib58","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/en.2014-1519","article-title":"The antidiabetic hormone glucagon-like peptide-1 induces formation of new elastic fibers in human cardiac fibroblasts after cross-activation of IGF-IR","volume":"156","author":"Qa'aty","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113236_bib59","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2018.01514","article-title":"Diabetic cardiomyopathy: current and future therapies. beyond glycemic control","volume":"9","author":"Borghetti","year":"2018","journal-title":"Front. Physiol."},{"issue":"10","key":"10.1016\/j.biopha.2022.113236_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078330","article-title":"Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms","volume":"8","author":"Picatoste","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdi.13098","article-title":"Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1\/p70 ribosomal protein S6 kinase pathway in diabetes mellitus","volume":"11","author":"Wang","year":"2020","journal-title":"J. Diabetes Invest."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2119\/molmed.2014.00259","article-title":"Glucagon-like peptide 1 protects against hyperglycemic-induced endothelial-to-mesenchymal transition and improves myocardial dysfunction by suppressing poly(ADP-ribose) polymerase 1 activity","volume":"21","author":"Yan","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2022.113236_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/630537","article-title":"Glucagon-like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway","volume":"2013","author":"Liu","year":"2013","journal-title":"J. Diabetes Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1758-5996-6-29","article-title":"Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats","volume":"6","author":"Guo","year":"2014","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.biopha.2022.113236_bib65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/JAHA.117.005945","article-title":"Alogliptin, a dipeptidyl peptidase-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits","volume":"6","author":"Zhang","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/abbs\/gmy177","article-title":"Liraglutide alleviates cardiac fibrosis through inhibiting P4h\u03b1-1 expression in STZ-induced diabetic cardiomyopathy","volume":"51","author":"Zhao","year":"2019","journal-title":"Acta Biochim Biophys. Sin. (Shanghai)"},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12763","article-title":"Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR\u03b1 pathway","volume":"17","author":"Wu","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.biopha.2022.113236_bib68","doi-asserted-by":"crossref","first-page":"7357096","DOI":"10.1155\/2016\/7357096","article-title":"Combined MSC and GLP-1 therapy modulates collagen remodeling and apoptosis following myocardial infarction","volume":"2016","author":"Wright","year":"2016","journal-title":"Stem Cells Int"},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib69","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.113.008364","article-title":"Cardiac fibroblast glycogen synthase kinase-3\u03b2 regulates ventricular remodeling and dysfunction in ischemic heart","volume":"130","author":"Lal","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib70","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10557-020-07006-9","article-title":"Exendin-4 attenuates remodeling in the remote myocardium of rats after an acute myocardial infarction by activating \u03b2-arrestin-2, protein phosphatase 2a, and glycogen synthase kinase-3 and inhibiting \u03b2-catenin","volume":"35","author":"Eid","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00395-015-0476-7","article-title":"Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix","volume":"110","author":"Robinson","year":"2015","journal-title":"Basic Res. Cardiol."},{"issue":"14","key":"10.1016\/j.biopha.2022.113236_bib72","first-page":"4648","article-title":"Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice","volume":"22","author":"Huang","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2022.113236_bib73","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.biopha.2022.113236_bib74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cells9040875","article-title":"Liver fibrosis: mechanistic concepts and therapeutic perspectives","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.113236_bib75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-385233-5.00006-4","article-title":"Fibrosis in the liver: acute protection and chronic disease","volume":"97","author":"Lee","year":"2010","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2022.113236_bib76","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","article-title":"Evolving challenges in hepatic fibrosis","volume":"7","author":"Friedman","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib77","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib78","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/liv.14799","article-title":"Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis","volume":"41","author":"Colosimo","year":"2021","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib79","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","article-title":"Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects","volume":"10","author":"Kawakubo","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/ars.2016.6953","article-title":"Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis, oxidative stress, and vascular dysfunction in models of nonalcoholic steatohepatitis and liver fibrosis","volume":"28","author":"Wang","year":"2018","journal-title":"Antioxid. Redox Signal."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2022.113236_bib82","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1665-2681(19)31820-4","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)","volume":"8","author":"Bellentani","year":"2009","journal-title":"Ann. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031394","article-title":"Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.biopha.2022.113236_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115246","article-title":"Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1\/2, p38\u03b1, and NF-\u03baB signaling","volume":"407","author":"Khalil","year":"2020","journal-title":"Toxicol. Appl. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2022.113236_bib87","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","article-title":"Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice","volume":"6","author":"Jouihan","year":"2017","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.biopha.2022.113236_bib88","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2337\/db14-0263","article-title":"SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis","volume":"63","author":"Xu","year":"2014","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib89","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbrc.2016.05.086","article-title":"GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK\/mTOR pathway","volume":"476","author":"He","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/en.2012-1937","article-title":"GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice","volume":"154","author":"Panjwani","year":"2013","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib92","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"issue":"12","key":"10.1016\/j.biopha.2022.113236_bib93","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"Trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib94","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.mehy.2004.11.048","article-title":"Adjuvant strategies for prevention of glomerulosclerosis","volume":"67","author":"McCarty","year":"2006","journal-title":"Med Hypotheses"},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib95","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/labinvest.2014.50","article-title":"Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction","volume":"94","author":"Min","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.biopha.2022.113236_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172844","article-title":"Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats","volume":"867","author":"Bai","year":"2020","journal-title":"Eur. J. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib97","doi-asserted-by":"crossref","first-page":"F1478","DOI":"10.1152\/ajprenal.00043.2020","article-title":"Inhibition of interleukin-6 on matrix protein production by glomerular mesangial cells and the pathway involved","volume":"318","author":"Chaudhari","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib98","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ajpath.2013.06.032","article-title":"miR-21-containing microvesicles from injured tubular epithelial cells promote tubular phenotype transition by targeting PTEN protein","volume":"183","author":"Zhou","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0084-3","article-title":"Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells","volume":"50","author":"Jia","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2022.113236_bib100","first-page":"1864107","article-title":"Glucagon-like peptide-1 mediates the protective effect of the dipeptidyl peptidase IV inhibitor on renal fibrosis via reducing the phenotypic conversion of renal microvascular cells in monocrotaline-treated rats","volume":"2018","author":"Xu","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib101","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3181\/0705-MR-134","article-title":"Diabetic nephropathy: mechanisms of renal disease progression","volume":"233","author":"Kanwar","year":"2008","journal-title":"Exp. Biol. Med."},{"issue":"9","key":"10.1016\/j.biopha.2022.113236_bib102","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.yexcr.2012.02.025","article-title":"Mesangial cell biology","volume":"318","author":"Abboud","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"9","key":"10.1016\/j.biopha.2022.113236_bib103","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.metabol.2011.01.010","article-title":"Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level","volume":"60","author":"Ishibashi","year":"2011","journal-title":"Metabolism"},{"issue":"14","key":"10.1016\/j.biopha.2022.113236_bib104","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1535370219876531","article-title":"Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca(2+) channel","volume":"244","author":"Huang","year":"2019","journal-title":"Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib105","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1159\/000341454","article-title":"Inhibition of the expression of TGF-\u03b21 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist","volume":"30","author":"Li","year":"2012","journal-title":"Cell Physiol. Biochem."},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib106","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000358623","article-title":"Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway","volume":"33","author":"Xu","year":"2014","journal-title":"Cell Physiol. Biochem."},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib107","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0002-9440(10)63909-0","article-title":"RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy","volume":"162","author":"Wendt","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib108","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3892\/ijmm.2014.2052","article-title":"Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells","volume":"35","author":"Zhao","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2022.113236_bib109","first-page":"15","article-title":"TGF-beta as a master regulator of diabetic nephropathy","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2017.11.076","article-title":"Recombinant human GLP-1(rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats","volume":"495","author":"Yin","year":"2018","journal-title":"Biochem Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2022.113236_bib111","doi-asserted-by":"crossref","first-page":"F614","DOI":"10.1152\/ajprenal.90500.2008","article-title":"C-peptide reverses TGF-beta1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy","volume":"296","author":"Hills","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"10193","key":"10.1016\/j.biopha.2022.113236_bib112","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113236_bib113","first-page":"1767","article-title":"GLP-1 receptor: a new target for sepsis","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113236_bib114","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2022.113236_bib115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1253\/circj.CJ-15-0718","article-title":"Plasma Glucagon-like peptide-1 and tissue characteristics of coronary plaque in non-diabetic acute coronary syndrome patients","volume":"80","author":"Mitsuhashi","year":"2016","journal-title":"Circ. J."},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib116","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.biopha.2022.113236_bib117","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/jmri.27009","article-title":"Effect of liraglutide on cardiovascular function and myocardial tissue characteristics in type 2 diabetes patients of south asian descent living in the netherlands: a double-blind, randomized, placebo-controlled trial","volume":"51","author":"Paiman","year":"2020","journal-title":"J. Magn. Reson Imaging"},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib118","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.biopha.2022.113236_bib119","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.biopha.2022.113236_bib120","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib121","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib122","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/jc.2002-021053","article-title":"Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5\u20136","key":"10.1016\/j.biopha.2022.113236_bib123","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.biocel.2005.09.011","article-title":"Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes","volume":"38","author":"Deacon","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113236_bib124","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis \u2014 a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113236_bib125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.pan.2013.07.281","article-title":"GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion","volume":"13","author":"Yang","year":"2013","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/labinvest.2013.133","article-title":"PSCs and GLP-1R: occurrence in normal pancreas, acute\/chronic pancreatitis and effect of their activation by a GLP-1R agonist","volume":"94","author":"Nakamura","year":"2014","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib127","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/14740338.2015.975205","article-title":"Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer","volume":"14","author":"Chalmer","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.biopha.2022.113236_bib128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2022.113236_bib129","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3892\/ol.2017.5752","article-title":"Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine","volume":"13","author":"Song","year":"2017","journal-title":"Oncol. Lett."},{"issue":"19","key":"10.1016\/j.biopha.2022.113236_bib130","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2022.113236_bib131","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00380-015-0734-5","article-title":"Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"31","author":"Nozue","year":"2016","journal-title":"Heart Vessels"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222006254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222006254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:23:24Z","timestamp":1791923004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222006254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":131,"alternative-id":["S0753332222006254"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113236","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113236"}}